ECM (extracellular matrix) composition for inhibiting light aging and application of ECM composition in skin care products
By using specific proportional compositions of type I, type III, type IV, type V collagen and elastin in skin care products, it effectively inhibits skin aging caused by ultraviolet radiation, and solves the problem of limited anti-aging effects of existing skin care products. , provides a scientific and efficient solution.
Patent Information
- Application Number
- CN202411114014.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-22
AI Technical Summary
Existing skin care products have limited effectiveness in inhibiting skin aging caused by ultraviolet radiation. They lack scientific combination ratios and cannot comprehensively improve skin aging problems.
The ECM composition consisting of 6 to 8 parts of type I collagen, 7 to 9 parts of type III collagen, 1 to 3 parts of type IV collagen, 2 to 4 parts of type V collagen and 8 to 10 parts of elastin was scientifically determined. The proportion of application in skin care products is to effectively inhibit ECM loss caused by photoaging.
At a concentration of 10 to 100 ppm, ECM compositions can significantly inhibit skin aging problems caused by ultraviolet radiation, have high safety and broad application prospects, and provide a more effective and scientific anti-aging solution.
Smart Images

Figure CN118986769A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of anti-aging, and in particular to an ECM composition for inhibiting photoaging and application thereof in skin care products. Background Art
[0002] Skin aging is divided into intrinsic aging and exogenous aging, of which exogenous aging is the most important. Exogenous aging is mainly caused by environmental factors, especially damage to the skin by ultraviolet (UV) radiation, namely photoaging. Photoaging is one of the main causes of skin aging and accounts for a large proportion of the total skin aging process. It causes significant changes in the skin, such as wrinkles, spots, decreased elasticity and roughness. In contrast, intrinsic aging is a natural aging process caused by the passage of time and genetic factors. Although it is inevitable, its impact is relatively small and progresses slowly.
[0003] At present, the market is in urgent need of more effective and scientific anti-aging solutions.
[0004] In view of this, the present invention is proposed. Summary of the invention
[0005] The object of the present invention is to provide an ECM composition for inhibiting photoaging and application thereof in skin care products.
[0006] The present invention is achieved in that:
[0007] In a first aspect, an embodiment of the present invention provides a composition comprising, by weight, at least three of the following components: 6 to 8 parts of type I collagen, 7 to 9 parts of type III collagen, 1 to 3 parts of type IV collagen, 2 to 4 parts of type V collagen and 8 to 10 parts of elastin.
[0008] In a second aspect, an embodiment of the present invention provides a skin care product or cosmetic, which includes: the composition described in the above embodiment.
[0009] In a third aspect, embodiments of the present invention provide use of the composition described in the preceding embodiments in the preparation of anti-aging products.
[0010] In a fourth aspect, embodiments of the present invention provide use of the composition as described in the preceding embodiments in inhibiting photoaging for purposes other than disease treatment or in preparing products that inhibit photoaging.
[0011] The present invention has the following beneficial effects:
[0012] The composition provided in the present application can effectively inhibit the loss of ECM (extracellular matrix) caused by photoaging at a concentration of 10 to 100 ppm, has high safety, can effectively inhibit or reduce skin aging problems caused by ultraviolet radiation, and has great application prospects in the preparation of skin care products or cosmetics with anti-aging effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0014] Figure 1 This is a graph showing the loss of ECM-related gene expression in human skin under photoaging conditions;
[0015] Figure 2 The expression diagram of COL1 gene in fibroblasts under different ratios of ECM combination;
[0016] Figure 3 The expression diagram of COL3 gene in fibroblasts under different ratios of ECM combination;
[0017] Figure 4 The expression diagram of COL4 gene in fibroblasts under different ratios of ECM combination;
[0018] Figure 5 The expression diagram of COL5 gene in fibroblasts under different ratios of ECM combination;
[0019] Figure 6 The expression diagram of ELN gene in fibroblasts under different ratios of ECM combination;
[0020] Figure 7 This is a radar chart of the loss inhibition rate of ECM-related genes in fibroblasts under different ratios of ECM combinations;
[0021] Figure 8 The content of MMP-1 in fibroblasts under different ratios of ECM combination;
[0022] Fig. 9 The figure shows the content of MMP-1 in fibroblasts under different concentrations of ECM golden ratio combination. DETAILED DESCRIPTION
[0023] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0024] Collagen is the main ingredient in many existing anti-aging skin care products. Some skin care products contain only one type of collagen, the most common of which is type I collagen. The effect of this product is relatively single and cannot comprehensively improve the various aging problems of the skin. Other skin care products mix multiple types of collagen, but these mixing ratios usually lack scientific basis and have limited effects, and cannot effectively deal with the skin aging problems caused by ultraviolet radiation. In this regard, the inventors of this application conducted a systematic analysis of the expression of ECM-related genes in the skin after photoaging based on the laboratory human skin transcriptome data, determined the loss of each ECM-related gene expression under photoaging conditions, and selected ECM raw materials that can be provided by cosmetic raw material suppliers for combination, and scientifically proposed an ECM composition that can inhibit the loss of ECM caused by photoaging. Applying it to anti-aging skin care products not only fills the gap in the existing market, but also provides a more effective and scientific anti-aging solution, which has broad application prospects and important market value.
[0025] On the one hand, an embodiment of the present invention provides a composition, which includes at least 3 of the following components, by weight: 6 to 8 parts of type I collagen, 7 to 9 parts of type III collagen, 1 to 3 parts of type IV collagen, 2 to 4 parts of type V collagen and 8 to 10 parts of elastin.
[0026] The applicant used ultraviolet (UV) to simulate photoaging, and took fibroblasts as the research object to study the anti-photoaging effect of the composition. It was found that the composition with the above weight ratio can effectively inhibit the loss of ECM caused by photoaging at a concentration of 10-100ppm, and the inhibition ability is better than that of ECM compositions with other ratios and single ECM components.
[0027] In some embodiments, the weight percentage of type I collagen can be any one of 6, 6.2, 6.4, 6.5, 6.6, 6.8, 7, 7.2, 7.4, 7.6, 7.8, 8 parts or a range between any two of them.
[0028] In some embodiments, the weight percentage of type III collagen can be any one of 7, 7.2, 7.4, 7.6, 7.8, 8, 8.2, 8.4, 8.6, 8.8, 9 parts or a range between any two of them.
[0029] In some embodiments, the weight percentage of type IV collagen can be any one of 1, 1.2, 1.4, 1.6, 1.8, 2, 2.2, 2.4, 2.6, 2.8, 3 parts or a range between any two of them.
[0030] In some embodiments, the weight percentage of type V collagen can be any one of 2, 2.2, 2.4, 2.6, 2.8, 3, 3.2, 3.4, 3.6, 3.8, 4 parts or a range between any two of them.
[0031] In some embodiments, the weight percentage of elastin can be any one of 8, 8.2, 8.4, 8.6, 8.8, 9, 9.2, 9.4, 9.6, 9.8, 10 parts or a range between any two of them.
[0032] In some embodiments, it includes at least 4 of the following components: 6 to 8 parts of type I collagen, 7 to 9 parts of type III collagen, 1 to 3 parts of type IV collagen, 2 to 4 parts of type V collagen, and 8 to 10 parts of elastin.
[0033] In some embodiments, the composition comprises, by weight: 6 to 8 parts of type I collagen, 7 to 9 parts of type III collagen, 1 to 3 parts of type IV collagen, 2 to 4 parts of type V collagen and 8 to 10 parts of elastin.
[0034] In some embodiments, the composition comprises, by weight: 6.5-7.5 parts of type I collagen, 7.5-8.5 parts of type III collagen, 1.5-2.5 parts of type IV collagen, 2.5-3.5 parts of type V collagen and 8.5-9.5 parts of elastin.
[0035] On the other hand, an embodiment of the present invention provides use of the composition as described in any of the above embodiments in preparing an anti-aging product.
[0036] In some embodiments, the anti-aging method comprises: inhibiting or reducing skin aging caused by ultraviolet radiation.
[0037] In some embodiments, the effective concentration of the composition is 10 to 100 ppm, which is the total protein concentration of type I collagen, type III collagen, type IV collagen, type V collagen and elastin, and can specifically be any one of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 ppm or a range between any two of them.
[0038] On the other hand, an embodiment of the present invention further provides use of the composition as described in any of the foregoing embodiments in inhibiting photoaging for non-disease treatment purposes or in preparing a product that inhibits photoaging.
[0039] In some embodiments, inhibiting photoaging includes: inhibiting ECM loss caused by photoaging.
[0040] In some embodiments, inhibiting photoaging includes: inhibiting the loss of ECM-related gene expression caused by photoaging.
[0041] In some embodiments, the ECM-related genes include any one or more of COL1, COL3, COL4, COL5 and ELN.
[0042] In some embodiments, the product comprises: a skin care product, a cosmetic, or a medicine.
[0043] In addition, an embodiment of the present invention further provides a skin care product or cosmetic, which includes: the composition described in any of the above embodiments.
[0044] In some embodiments, the skin care product comprises any one of: lotion, facial cream, eye cream, facial mask, hydrating spray, body lotion and hand cream.
[0045] In some embodiments, the cosmetic comprises any one of lotion and liquid foundation.
[0046] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0047] Example 1
[0048] 1.1 Determination of the loss of ECM-related gene expression under photoaging
[0049] Based on the laboratory preliminary data, this example analyzes the gene expression profile of human skin before and after photoaging, determines the loss of expression of each ECM-related gene under photoaging conditions, and selects ECM raw materials that can be provided by cosmetic raw material suppliers for analysis and mapping (Table 1 and Figure 1 ).
[0050] Table 1 Loss of expression of some ECM-related genes
[0051] Gene The average expression level of the control group Average expression level in photoaging group Loss COL1 17.58 16.10 1.48 COL3 25.09 23.38 1.71 COL4 4.05 3.64 0.41 COL5 13.67 13.13 0.54 ELN 19.37 17.55 1.82
[0052] 1.2 Calculation of the ECM golden ratio for the loss of ECM-related gene expression in photoaging
[0053] First, the loss of the above-mentioned ECM-related genes (COL1, COL3, COL4, COL5, ELN) was divided by the minimum loss value of 0.41, and then the obtained values were multiplied by 2 for amplification. Finally, the obtained values were rounded off to an integer ratio, that is, 7:8:2:3:9, which is used as the ECM golden ratio for ECM loss due to photoaging.
[0054] Table 2 Calculation of ECM golden ratio
[0055] COL1 COL3 COL4 COL5 ELN Loss 1.48 1.71 0.41 0.54 1.82 Divide by 0.41 3.61 4.17 1.00 1.32 4.41 Multiply by 2 7.22 8.34 2.00 2.63 8.83 rounding 7 8 2 3 9
[0056] Example 2
[0057] 2.1 Experimental Purpose
[0058] In this experiment, after drug treatment, fibroblasts were treated with UV modeling to simulate photoaging. After a certain period of culture, the expression levels of ECM-related genes in the cells were detected to evaluate the ability of the ECM composition to inhibit the loss of ECM proteins caused by photoaging.
[0059] 2.2 Experimental Materials
[0060] 2.2.1 Cell types
[0061] The cell type used in this experiment is human dermal fibroblasts (HDF cells), which were purchased from ScienCell (Cat. No. 2320). Fibroblasts were cultured in vitro using FM medium. The cells are adherent cells with elongated cell bodies, pointed ends, and spindle-shaped.
[0062] 2.2.2 Main reagents
[0063] Table 3 Main reagents
[0064]
[0065]
[0066] 2.2.3 Main consumables
[0067] Table 4 Main consumables
[0068] Consumables Name brand Part Number 6-well cell culture plate Corning 3516 24-well cell culture plates Corning 3526 15mL centrifuge tube Corning 430791 50mL centrifuge tube Corning 430828 PCR tubes Corning PCR-02-C <![CDATA[MicroAmp TM Optical 96-well reaction plate]]> <![CDATA[Applied Biosystems TM ]]> 4306737 <![CDATA[MicroAmp TM Optical Adhesive Sealing Film]]> <![CDATA[Applied Biosystems TM ]]> 4311971
[0069] 2.2.4 Main equipment
[0070] Table 5 Main equipment list
[0071] Device Name brand model Biological Safety Cabinets Thermo Fisher Scientific <![CDATA[MSC-Advantage TM ]]> Cell culture incubator Thermo Fisher Scientific BB150 Centrifuge Thermo Fisher Scientific Sorvall ST8 Refrigerated centrifuge Thermo Fisher Scientific H1650 Inverted microscope Olympus CKX41 Cell Counter Countstar Mira FL UV irradiator VILBER BIO-SUN Ultra-micro UV spectrophotometer Thermo Fisher Scientific NanoDrop One Gradient PCR instrument Takara TP600 Real-time fluorescence quantitative PCR system Applied Biosystems StepOnePlus
[0072] 2.2.5 Sample information
[0073] Table 6 Sample information table
[0074] Sample name source Physical and chemical properties content Storage conditions Recombinant collagen type I Juyuan Biology powder 100% 4℃ Recombinant collagen type III Juyuan Biology powder 100% 4℃ Recombinant collagen type IV Juyuan Biology liquid 0.6% 4℃ Recombinant collagen type V Juyuan Biology powder 100% 4℃ Recombinant elastin Jiuqian Chemical liquid 0.1% 4℃
[0075] 2.3 Fibroblast gene expression level test
[0076] 2.3.1 Experimental methods
[0077] (1) Cell seeding: HDF cells grown in FM medium were plated at 6×10 4 The cells were inoculated at a density of 100 cells / mL in a 6-well cell culture plate, 2 mL per well, and cultured in a cell culture incubator for 24 h.
[0078] (2) Experimental grouping: As shown in the experimental grouping table (Table 7), the experiment set up a blank control group, a UV model group, an ECM golden ratio group, an ECM equal ratio group, a recombinant type I collagen group, a recombinant type III collagen group, a recombinant type IV collagen group, a recombinant type V collagen group, and a recombinant elastin group. The total concentration of ECM protein in each sample group was set to 50 ppm, and 3 replicate wells were set.
[0079] Table 7 Experimental grouping table
[0080]
[0081]
[0082] (3) Sample preparation: See Table 6 for sample information. Recombinant type I collagen, recombinant type III collagen, recombinant type IV collagen, recombinant type V collagen, and recombinant elastin were diluted to 1000 ppm using PBS buffer.
[0083] (4) Drug administration: The samples were administered according to the final concentrations in the experimental grouping table (Table 7). The blank control group and UV model group were added with an equal volume of PBS and cultured in a cell culture incubator for 24 h.
[0084] (5) UV modeling: Discard the culture medium in the cell culture plate, add 2 mL of PBS buffer to each well, and place in a UV irradiator for modeling. The UV dose is set to 15 mJ / cm2. After irradiation, remove the cell culture plate, discard the PBS, and add 2 mL of new FM culture medium to each well.
[0085] (6) RNA extraction and cDNA synthesis: RNA was extracted using the TaKaRa MiniBEST Universal RNA Extraction Kit, and then PrimeScript TM The RT reagent Kit with gDNAEraser kit synthesizes the extracted RNA into cDNA. The specific operation method refers to the kit instructions.
[0086] (7) Detection of gene expression: Using TB Premix Ex Taq TM The kit was used to detect the expression levels of COL1, COL3, COL4, COL5, and ELN genes, GAPDH was used as the internal reference gene, and the reaction system of fluorescence quantitative PCR was set to 10 μL (Table 8). The gene expression level was detected on the real-time fluorescence quantitative PCR system, and the reaction program was as follows: 95°C for 30 s, 40 cycles (95°C for 5 s, 54°C for 30 s). 2- ΔΔ The relative expression level of genes was calculated by the Ct method.
[0087] Table 8 Fluorescence quantitative PCR reaction system
[0088] Reagent name Volume (μL) TB Green 5 water 3.4 Rox 0.2 Forward Primer 0.2 Post Primer 0.2 cDNA 1
[0089] 2.3.2 Results Statistics and Analysis
[0090] GraphPad Prism software was used for plotting, and the results of gene expression were expressed as Mean ± SD. The significant difference between the two groups of data was analyzed using t test. The calculation formula for the loss inhibition rate of each ECM-related gene expression was: Loss inhibition rate (%) = (gene expression level of the drug group - gene expression level of the UV model group) / (gene expression level of the blank control group - gene expression level of the UV model group).
[0091] 2.3.3 Experimental results
[0092] After different sample treatments, the relative expression levels of COL1, COL3, COL4, COL5, and ELN genes are shown in Table 1. Figure 2-6 In general, the overall expression level of ECM-related genes in the ECM golden ratio group was higher than that in the ECM equal ratio group, recombinant type I collagen group, recombinant type III collagen group, recombinant type IV collagen group, recombinant type V collagen group, and recombinant elastin group.
[0093] In addition, the ECM-related gene expression loss inhibition rate of each sample group under photoaging conditions was calculated (Table 9). Except for the COL1 gene, the loss inhibition rates of COL3, COL4, COL5, and ELN genes in the ECM golden ratio group were higher than those in the ECM equal ratio group, recombinant type I collagen group, recombinant type III collagen group, recombinant type IV collagen group, recombinant type V collagen group, and recombinant elastin group. In order to make the display of the experimental results more intuitive, the data results were also plotted as a radar chart ( Figure 7 ).
[0094] Table 9 Summary of inhibition rate of ECM-related gene expression loss under photoaging conditions
[0095]
[0096] Example 3
[0097] 3.1 Experimental Purpose
[0098] In order to compare the inhibitory ability of the ECM golden ratio group and other ECM protein combinations on ECM loss caused by photoaging, this example selects matrix metalloproteinase 1 (MMP-1) as an evaluation index. MMP-1 is a collagenase that can degrade a variety of ECM components, especially type I collagen and type III collagen. Therefore, the level of ECM degradation can be evaluated by detecting the indicator of MMP-1, thereby evaluating the inhibitory ability of different compositions on ECM loss.
[0099] 3.2 Experimental methods
[0100] For detailed information on experimental reagents, consumables, equipment, samples, etc., please see Tables 3-6 in Example 2.
[0101] HDF cells were cultured at 5 × 10 4 The cells were inoculated at a density of 100 / mL in a 24-well cell culture plate, 1 mL per well, and cultured for 24 hours. The drugs were administered according to the ratio in Table 10, with a total concentration of 50 ppm for each group of samples, 3 replicate wells were set for each group, and cultured for 24 hours. The cells were placed in a UV modeling instrument for UV modeling, and the UV dose was set to 15 mJ / cm 2 The cells were cultured for 24 h. The cell supernatant was collected and the content of MMP-1 was determined according to the instructions of the ELISA kit.
[0102] Table 10 Experimental grouping table
[0103]
[0104]
[0105] 3.3 Experimental Results
[0106] like Figure 8 As shown in the figure, UV modeling increased the MMP-1 content by 80.2%, indicating that the photoaging model was successfully established. Compared with the UV model group, the MMP-1 content in the ECM golden ratio group decreased by 51.0%, and the MMP-1 content was significantly lower than that in the ECM equal ratio group and the ECM combination of 3 or 4 components. The above results show that the ECM golden ratio group can effectively inhibit the ECM loss caused by photoaging, and its inhibitory ability is better than that of the ECM equal ratio group and the ECM combination of 3 or 4 components.
[0107] Example 4
[0108] 4.1 Experimental Purpose
[0109] This example is to evaluate the ability of the ECM golden ratio group to inhibit collagen loss at different concentrations. This experiment set three concentrations of 10, 50, and 100 ppm.
[0110] 4.2 Experimental methods
[0111] For detailed information on experimental reagents, consumables, equipment, samples, etc., please refer to Tables 3 to 6 in Example 2.
[0112] HDF cells were cultured at 5 × 10 4 The cells were inoculated at a density of 100 / mL in a 24-well cell culture plate, 1 mL per well, and cultured for 24 hours. The drugs were administered according to Table 11, with three concentrations of 10, 50, and 100 ppm set in the drug administration group, 3 replicates were set in each group, and cultured for 24 hours. The cells were placed in a UV modeling instrument for UV modeling, and the UV dose was set to 15 mJ / cm 2 The cells were cultured for 24 h. The cell supernatant was collected and the content of MMP-1 was determined according to the instructions of the ELISA kit.
[0113] Table 11 Experimental grouping table
[0114]
[0115]
[0116] 4.3 Experimental Results
[0117] like Fig. 9 As shown, UV modeling increased the MMP-1 content by 80.2%, indicating that the photoaging model was successfully modeled. Compared with the UV model group, the MMP-1 content in the ECM golden ratio groups at concentrations of 10, 50, and 100 ppm decreased by 11.2%, 51.0%, and 52.5%, respectively. The above results show that the ECM golden ratio group can effectively inhibit the ECM loss caused by photoaging at a concentration of 10-100ppm. Compared with 10ppm, the content of MMP-1 at a concentration of 50ppm has decreased significantly, but as the concentration increases to 100ppm, the content of MMP-1 has not increased significantly. Therefore, the applicant believes that 50ppm is a concentration with a high application cost-effectiveness.
[0118] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A composition, characterized in that In terms of weight, it comprises at least three of the following components: 6 to 8 parts of type I collagen, 7 to 9 parts of type III collagen, 1 to 3 parts of type IV collagen, 2 to 4 parts of type V collagen and 8 to 10 parts of elastin.
2. The composition according to claim 1, characterized in that It comprises at least 4 of the following components: 6 to 8 parts of type I collagen, 7 to 9 parts of type III collagen, 1 to 3 parts of type IV collagen, 2 to 4 parts of type V collagen and 8 to 10 parts of elastin.
3. The composition according to claim 1, characterized in that The composition comprises, by weight: 6 to 8 parts of type I collagen, 7 to 9 parts of type III collagen, 1 to 3 parts of type IV collagen, 2 to 4 parts of type V collagen and 8 to 10 parts of elastin.
4. The composition according to claim 1, characterized in that The composition comprises, by weight: 6.5 to 7.5 parts of type I collagen, 7.5 to 8.5 parts of type III collagen, 1.5 to 2.5 parts of type IV collagen, 2.5 to 3.5 parts of type V collagen and 8.5 to 9.5 parts of elastin.
5. A skin care product or cosmetic, characterized in that: The active ingredients thereof include: the composition according to any one of claims 1 to 4.
6. Use of the composition according to any one of claims 1 to 4 in the preparation of anti-aging products.
7. The use according to claim 6, characterized in that: The anti-aging includes: inhibiting or reducing skin aging caused by ultraviolet radiation; Optionally, the composition has an effective concentration of 10 to 100 ppm.
8. Use of the composition according to any one of claims 1 to 4 in inhibiting photoaging for purposes other than disease treatment or in preparing products for inhibiting photoaging.
9. The use according to claim 8, characterized in that: The inhibiting of photoaging comprises: inhibiting the loss of extracellular matrix caused by photoaging; Optionally, the inhibiting photoaging comprises: inhibiting the loss of expression of extracellular matrix-related genes caused by photoaging; Optionally, the extracellular matrix-related genes include any one or more of COL1, COL3, COL4, COL5 and ELN.
10. The use according to claim 6 or 8, characterized in that: The products include: skin care products, cosmetics or medicines.
Citation Information
Patent Citations
Extracellular matrix compositions
CN106794227A
Composite collagen composition and preparation method thereof
CN115671390A
Collagen-containing skin repair composition
CN116869855A
Bionic 6D recombinant collagen as well as preparation method and application thereof
CN118356368A
Collagen complex and method for producing cosmetic composition containing the same
JP2022183243A
